Weight cycling is a pattern in which individuals repeatedly lose and regain body weight. Researchers have found in a new ...
Learn how chronic kidney disease and diabetes accelerate heart risk, with new research revealing early warning signs.
The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.
defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation compared with baseline, onset of persistent ...
Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight ...
Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Empagliflozin and dapagliflozin are equally effective in reducing the long-term risks of acute kidney injury (AKI) and chronic kidney disease (CKD ... estimated glomerular filtration rate [eGFR], ...
Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease ... eGFR less than 15 mL/min/1.73 m 2. Outcomes related to CV or renal death, as well as chronic ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Body-weight Cycling and Risk of Diabetic Kidney Disease in People With Type 1 Diabetes in the DCCT/EDIC Population. The Journal of Clinical Endocrinology & Metabolism , 2025; DOI: 10.1210/clinem ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results